Lucy Therapeutics validates new mitochondrial-based therapeutic approach for Parkinson's disease

Oct. 14, 2022

Lucy Therapeutics Inc. has announced promising preclinical data for multiple compounds in its lead program for Parkinson's disease, including two lead small-molecule agents, LucyTx-1209 and LucyTx-1212.

BioWorld Science Neurology/psychiatric

Today's news in brief

BioWorld

BioWorld briefs for Dec. 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 9, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

ASH 2025: New blood cancer therapies trump chemo, older drugs

BioWorld

Targeted therapies and immunotherapies continue to show better results than chemotherapy in investigator-initiated and company-sponsored cancer trials, and newer...